Canmab 150 mg Injection

Canmab 150 mg Injection contains Trastuzumab, a targeted monoclonal antibody used to treat HER2-positive breast and gastric cancers by binding to the HER2 receptor and blocking signals that promote cancer cell growth and survival. Given as an intravenous infusion under medical supervision, it helps slow tumor progression and improve treatment outcomes, with dosing scheduled weekly or every three weeks based on the treatment plan. Common side effects include fever, headache, cough, rash, infections, and sleep disturbances, while serious risks such as heart or lung problems require close monitoring; Canmab is not recommended during pregnancy and should never be self-administered.